使用基因激活 crispr 过度表达长非编码 rna

Executive Industry Relevance

Overexpressing long noncoding RNAs (lncRNAs) using CRISPR activation enables functional interrogation of disease-associated transcripts without cDNA limitations, supporting target validation in discovery pipelines. This approach addresses challenges posed by low expression, tissue specificity, and isoform complexity, providing a mechanism to assess lncRNA involvement in inflammatory pathways. By leveraging endogenous splicing, the method enhances predictive confidence in preclinical models and supports mechanistic de-risking of lncRNA targets.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of lncRNA function in disease-relevant contexts such as inflammatory bowel disease using IFNG-AS1 as a model.
• Operational Value: Supports overexpression of multiple endogenous splice forms, increasing confidence in target engagement and pathway modulation.
• Scientific Value: Facilitates biological de-risking by linking lncRNA overexpression to downstream phenotypic readouts like cytokine production.

Screening & Assay Development

• Scientific Value: Generates standardized, inducible overexpression systems suitable for high-content screening of lncRNA-modulating compounds.
• Operational Value: Produces quantifiable outputs via RT-qPCR with housekeeping gene normalization, enabling dose-response and temporal expression profiling.
• Scientific Value: Ensures expression of native isoforms, improving assay relevance compared to ectopic cDNA approaches.

Translational & Preclinical Research

• Scientific Value: Uses human Jurkat T-cells, enhancing translational relevance for immune-mediated diseases.
• Operational Value: Enables clonal expansion and selection, supporting consistent preclinical model generation.
• Scientific Value: Links lncRNA overexpression to functional immune outputs, supporting biomarker-aligned mechanism of action studies.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target hypothesis testing to lead identification, particularly for noncoding RNA targets where traditional overexpression fails.

• Discovery Biology: Supports hypothesis testing by enabling controlled overexpression of lncRNAs to assess phenotypic consequences in immune cells.
• Screening: Produces reproducible, inducible expression systems amenable to compound library screening for modulators of lncRNA activity.
• Analytics: Delivers quantitative, normalized gene expression data via RT-qPCR, facilitating comparison across conditions and clones.
• Translational Research: Uses human T-cell model, enabling direct relevance to inflammatory disease pathways and preclinical validation.
• Enterprise Reuse: Establishes a modular platform for lncRNA overexpression applicable across multiple targets and cell types.

Operational & Enterprise Impact

• Scientific Value: Increases target validation confidence by enabling physiologic overexpression of multiple lncRNA isoforms.
• Operational Value: Provides a standardized, lentiviral-based system for consistent, scalable overexpression across experiments.
• Strategic Value: Reduces false negatives in target assessment by overcoming limitations of low-abundance lncRNA detection.
• Portfolio Impact: Supports go/no-go decisions in lncRNA target programs by providing mechanistic insight prior to investment.

Implementation Considerations

• Requires expertise in molecular cloning, lentiviral production, and CRISPR-based transcriptional activation.
• Necessitates biosafety level 2 (BSL-2) facilities for handling lentiviral vectors and human cell lines.
• Depends on accurate gRNA design within 100 bp of transcriptional start site for effective activation.
• Requires validation of overexpression via isoform-specific or pan-transcript RT-qPCR with appropriate controls.
• Involves multi-day workflow including virus production, transduction, selection, and clonal expansion.

Biopharma FAQs